# Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy

> **NCT03395873** · PHASE1 · TERMINATED · sponsor: **Milton S. Hershey Medical Center** · enrollment: 7 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03395873
- **Lead sponsor:** Milton S. Hershey Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-29
- **Primary completion:** 2019-05-15
- **Final completion:** 2019-05-15
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Recent FDA approval of a new drug for the same patient population
- **Last updated:** 2019-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03395873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03395873, "Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT03395873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*